title: Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
abstract: Finding new therapies for Parkinson's disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used, or being developed, in other therapeutic areas, as well as considering several natural, non-pharmaceutical compounds. The committee prioritized which of these putative treatments were most suited to move immediately into pilot clinical trials. Aspects considered included known modes of action, safety, blood-brain-barrier penetration, preclinical data in animal models of PD and the possibility to monitor target engagement in the brain. Of the 26 potential interventions, 10 were considered worth moving forward into small, parallel 'learning' clinical trials in PD patients. These trials could be funded in a multitude of ways through support from industry, research grants and directed philanthropic donations. The committee-based approach to select the candidate compounds might help rapidly identify new potential PD treatment strategies for use in clinical trials.
authors.affiliation: Center for Neurodegenerative Science, Van Andel Institute, MI, USA.
authors.forename: Patrik
authors.initials: P
authors.lastname: Brundin
authors.forename: Roger A
authors.initials: RA
authors.lastname: Barker
authors.forename: P Jeffrey
authors.initials: PJ
authors.lastname: Conn
authors.forename: Ted M
authors.initials: TM
authors.lastname: Dawson
authors.forename: Karl
authors.initials: K
authors.lastname: Kieburtz
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Lees
authors.forename: Michael A
authors.initials: MA
authors.lastname: Schwarzschild
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Tanner
authors.forename: Tom
authors.initials: T
authors.lastname: Isaacs
authors.forename: Joy
authors.initials: J
authors.lastname: Duffen
authors.forename: Helen
authors.initials: H
authors.lastname: Matthews
authors.forename: Richard K H
authors.initials: RK
authors.lastname: Wyse
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D011446:Prospective Studies
chemical_list: D000978:Antiparkinson Agents
references.citation: Nat Rev Drug Discov. 2004 Aug;3(8):673-83
references.pmid: 15286734
references.citation: Nature. 2009 Nov 12;462(7270):175-81
references.pmid: 19881490
references.citation: Biochemistry. 2010 Dec 7;49(48):10267-76
references.pmid: 21058655
references.citation: J Endocrinol. 2009 Sep;202(3):431-9
references.pmid: 19570816
references.citation: Nat Rev Drug Discov. 2004 Aug;3(8):711-5
references.pmid: 15286737
references.citation: J Pharmacol Exp Ther. 2009 May;329(2):404-11
references.pmid: 19182069
references.citation: Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1285-90
references.pmid: 19164583
references.citation: J Pharmacol Exp Ther. 2008 Apr;325(1):1-9
references.pmid: 18202293
references.citation: J Clin Invest. 2013 Jun;123(6):2364-5
references.pmid: 23728166
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):881-8
references.pmid: 12183643
references.citation: Ann Neurol. 2005 Feb;57(2):197-203
references.pmid: 15668964
references.citation: Trials. 2012 Sep 15;13:168
references.pmid: 22978443
references.citation: Diabetes Obes Metab. 2010 Sep;12(9):815-24
references.pmid: 20649634
references.citation: ChemMedChem. 2009 Apr;4(4):680-6
references.pmid: 19266525
references.citation: J Neurosci Res. 2008 Feb 1;86(2):326-38
references.pmid: 17803225
references.citation: Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19
references.pmid: 21701501
references.citation: Neurology. 2006 Mar 14;66(5):664-71
references.pmid: 16481597
references.citation: Nat Rev Drug Discov. 2011 May;10(5):328-9
references.pmid: 21532551
references.citation: Stroke. 2007 Feb;38(2 Suppl):800-3
references.pmid: 17261742
references.citation: Clin Neuropharmacol. 2008 May-Jun;31(3):141-50
references.pmid: 18520981
references.citation: Metab Eng. 2008 Jan;10(1):1-9
references.pmid: 17962055
references.citation: Nat Rev Drug Discov. 2005 Dec;4(12):1005-14
references.pmid: 16341065
references.citation: Mov Disord. 2012 Nov;27(13):1606-11
references.pmid: 23115047
references.citation: Nat Rev Drug Discov. 2011 Aug 31;10(9):712
references.pmid: 21892149
references.citation: Nature. 2012 Jun 10;486(7403):361-7
references.pmid: 22722194
references.citation: J Pharmacol Exp Ther. 2011 Jan;336(1):3-8
references.pmid: 20739456
references.citation: Drug Discov Today Ther Strateg. 2011 Winter;8(3-4):61-69
references.pmid: 22368688
references.citation: Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11178-83
references.pmid: 22711801
references.citation: Prog Neurobiol. 2011 Dec;95(4):629-35
references.pmid: 21930184
references.citation: Expert Rev Clin Pharmacol. 2012 Sep;5(5):481-3
references.pmid: 23121265
references.citation: J Clin Invest. 2013 Jun;123(6):2730-6
references.pmid: 23728174
references.citation: Neurology. 2006 Mar 14;66(5):628-33
references.pmid: 16534099
references.citation: J Neuroinflammation. 2008 May 21;5:19
references.pmid: 18492290